Solstein Capital LLC Cuts Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Solstein Capital LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 19.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,837 shares of the company's stock after selling 5,000 shares during the period. Novo Nordisk A/S accounts for 1.0% of Solstein Capital LLC's investment portfolio, making the stock its 24th biggest position. Solstein Capital LLC's holdings in Novo Nordisk A/S were worth $1,792,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. GQG Partners LLC increased its stake in Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after acquiring an additional 5,556,460 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after purchasing an additional 2,947,771 shares in the last quarter. Folketrygdfondet increased its position in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock valued at $765,917,000 after purchasing an additional 40,313 shares during the last quarter. Sustainable Growth Advisers LP raised its holdings in shares of Novo Nordisk A/S by 23.6% during the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock valued at $459,416,000 after buying an additional 1,021,498 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $404,910,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Novo Nordisk A/S Stock Down 2.2 %

Shares of NVO stock traded down $1.41 during midday trading on Tuesday, reaching $62.23. 4,076,030 shares of the stock were exchanged, compared to its average volume of 8,447,661. Novo Nordisk A/S has a 1 year low of $60.61 and a 1 year high of $148.15. The firm has a market cap of $279.28 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The company's 50 day moving average is $80.37 and its two-hundred day moving average is $95.75. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a $0.7874 dividend. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's payout ratio is currently 47.72%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on NVO shares. StockNews.com raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Monday. UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a report on Monday, December 23rd. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.